

Catalog Number: CM03367

产品信息


Catalog Number:
CM03367

CAS号:
902135-91-5

分子式:
C₁₆H₁₈Cl₃N₅O₂
主要靶点:
Apoptosis|CDK|GSK-3

主要通路:
干细胞|凋亡|PI3K/Akt/mTOR信号
通路|细胞周期

分子量:
418.71

溶解度:
DMSO:52 mg/mL (124.19
mM),warmed,Ethanol:28 mg/mL
(66.87 mM),warmed,H₂O:1
mg/mL (2.38 mM),warmed


靶点活性

CDK2/CyclinA:47 nM|CDK9/CyclinT:<10 nM|GSK-3 β :89 nM|CDK5/p35:13 nM|CDK4/CyclinD1:100 nM

体外活性

AT7519 is an ATP competitive CDK inhibitor with a Ki value of 38 nM for CDK1. AT7519 is inactive against all non-CDK kinases with the exception of GSK3 β (IC₅₀ = 89 nM). AT7519 shows potent antiproliferative activity in a variety of human tumor cell lines with IC₅₀ values ranging from 40 nM for MCF-7 to 940 nM for SW620 consistent with the inhibition of CDK1 and CDK2. [1] AT7519 induces dose-dependent cytotoxicity in multiple myeloma (MM) cell lines with IC₅₀ values ranging from 0.5 to 2 μ M at 48 hours, with the most sensitive cell lines being MM.1S (0.5 μ M) and U266 (0.5 μ M) and the most resistant MM.1R (>2 μ M). It does not induce cytotoxicity in peripheral blood mononuclear cells (PBMC). AT7519 partially overcomes the proliferative advantage conferred by IL6 and IGF-1 as well as the protective effect of bone marrow stromal cells (BMSCs). AT7519 induces rapid dephosphorylation of RNA pol II CTD at serine 2 and serine 5 sites, and leads to the inhibition of transcription, partially contributing to AT7519 induced cytotoxicity of MM cells. AT7519 induces activation of GSK-3 β by down-regulating GSK-3 β phosphorylation, which also contributes to AT7519 induced apoptosis independent of the inhibition of transcription. [2]

体内活性

A twice daily dosing of AT7519 (9.1 mg/kg) causes tumor regression of both early-stage and advanced-stage s.c. tumors in the HCT116 and HT29 colon cancer xenograft models. [1] AT7519 treatment (15 mg/kg) inhibits tumor growth and prolongs the median overall survival of mice in the human MM xenograft mouse model in association with increased caspase 3 activation. [2]

细胞实验

Cells are incubated with different concentrations of AT7519 for 24 or 48 hours at 37°C. Cell viability is assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) dye absorbance. DNA synthesis is measured by tritiated thymidine uptake (³H-TdR). Apoptosis is assessed by using Annexin V/PI staining. The percentage of cells undergoing apoptosis is defined as the sum of early apoptosis (Annexin V-positive cells) and late apoptosis (Annexin V-positive and PI-positive cells)(Only for Reference)

描述

AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.

储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years